Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.
about
Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris.Adenovirus F protein as a delivery vehicle for botulinum BSynergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.Botulinum toxin: bioweapon & magic drugCharacterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast.Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.Subunit vaccine efficacy against Botulinum neurotoxin subtypes.Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal routeNew equine antitoxins to botulinum neurotoxins serotypes A and B.Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens.Subunit vaccine against the seven serotypes of botulismOral vaccination with an adenovirus-vectored vaccine protects against botulism.Characterization of new formalin-detoxified botulinum neurotoxin toxoidsEvaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticlesQuantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodiesCandidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector systemRecombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity
P2860
Q25257023-2BFDD943-9EE8-4879-8939-8A4C58371162Q33627014-DB4609F8-C525-4BE7-B95D-6394F67FF419Q33888291-9599F520-C22C-4225-A718-72FBFD0C054AQ34033221-1D42195D-F504-49F1-9522-C2DFE90111F7Q34530009-48091BF9-F898-43F8-A475-B3229A8D947CQ34865019-5028E556-C57A-4725-8E7C-0FB5CE710D9EQ35043107-D5DF131E-93DD-4BDD-B5D8-A5DAC9250172Q35139316-3EEB2DF2-5CE1-4439-9AFA-E1B850A674F9Q35532054-DBC6EDFD-34F2-43AC-A6E1-AAD4798C371AQ35722157-C1D2C3E6-6780-4111-8CF8-08BD88E55471Q35869311-F0884FFE-66AF-4D5F-8612-86DD5BCC120CQ35886818-0C122360-E2F9-41DB-82EB-B8F4E2EE7B57Q35913397-29D58494-01C1-45E9-B328-599F5FD3D16EQ36087224-05747641-0E45-471B-8DA1-A51949D7DCA8Q36143517-C38BA5DF-87E1-4683-8AF0-07C50CE46F77Q36391905-18E640B6-E41F-4C8C-9F41-7D6209F737FAQ36483548-14164894-FA11-4210-AE39-1A2610F5C228Q36734902-EF809C82-F3E8-4EDF-8A36-5B8CF9CB2892Q36898034-CB41C287-B28F-40E7-A488-41E8CA987198Q36994248-BCA3E8E4-4F48-4AC4-8FDF-0A1BA3D83D91Q37130982-B6190716-01DA-4122-A57B-927DC688ABF3Q37308221-BA723E71-B569-4B88-A9E1-75BB3F914121Q39521997-E2098C6D-EBE3-43EB-9063-FEB2DB2C34F4Q40068037-312965E6-F77D-4AA4-9018-0C5BA58C6C3DQ42573272-5EA31CE5-FC53-498F-90CF-D8F0A0235C07Q42600051-F2C342F3-49F9-4AAE-909F-83AC648BAB48Q43097051-8B3F5714-26E5-470C-A9C5-69207F3B2149Q57177243-AE453D21-8736-411C-A55A-64BA4155C57F
P2860
Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Purification, potency, and eff ...... recombinant vaccine candidate.
@ast
Purification, potency, and eff ...... recombinant vaccine candidate.
@en
type
label
Purification, potency, and eff ...... recombinant vaccine candidate.
@ast
Purification, potency, and eff ...... recombinant vaccine candidate.
@en
prefLabel
Purification, potency, and eff ...... recombinant vaccine candidate.
@ast
Purification, potency, and eff ...... recombinant vaccine candidate.
@en
P2093
P2860
P1476
Purification, potency, and eff ...... recombinant vaccine candidate
@en
P2093
V A Montgomery
P2860
P304
P407
P577
1998-10-01T00:00:00Z